Moraxella catarrhalis pneumonia
ICD-10 J16.8 · ICD-11 CA40.0&XN90V

Treatment of Moraxella catarrhalis Pneumonia in Adults with Comorbidities (Outpatient Community-Acquired Pneumonia)

This protocol addresses community-acquired Moraxella catarrhalis pneumonia managed in the outpatient setting in adults who carry one or more underlying conditions that influence empiric antibiotic selection.

The protocol applies to adult outpatients with community-acquired pneumonia who have at least one of the following comorbidities: chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia. The presence of these conditions places patients in a higher-risk category and directly determines the recommended empiric treatment approach.

Treatment Approach (Partial Overview)

Recommended management involves empiric antibiotic therapy structured as either a combination regimen — pairing a beta-lactam or cephalosporin with a second class of agent — or monotherapy with a respiratory-class agent. The complete agent selection, sequencing criteria, and full duration guidance are detailed in the structured protocol.

Clinical stability targets: Resolution of vital sign abnormalities — heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature — along with restoration of normal mentation and the ability to eat. Most patients reach clinical stability within the first 48 to 72 hours.
Instant Access to Structured Evidence-Based Regimens

References

For outpatient adults with comorbidities such as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; or asplenia we recommend (in no particular order of preference) (Table 3):

A variety of criteria for determining clinical improvement have been developed for patients with CAP and validated in clinical trials, including resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation.

As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.

DOI: 10.1164/rccm.201908-1581ST

View source ↗